A Phase II Trial of Alimta (Pemetrexed) in Patients With Recurrent Malignant Gliomas, Primary Central Nervous System Lymphoma, and Brain Metastases
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Pemetrexed (Primary)
- Indications Cancer metastases; CNS cancer; Glioma; Lymphoma; Solid tumours
- Focus Therapeutic Use
- 26 May 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 26 May 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 26 Jun 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.